These findings indicated that SMYD2 might methylate multiple non‐histone proteins involved in proliferation/survival of NSCLC cells, as we reported previously, and treatment with SMYD2 inhibitor would be beneficial to NSCLC patients regardless of harboring EML4‐ALK fused proteins. This evidence concerns the gene ALK and non-small cell lung carcinoma.